PTCT Q4 2022 Earnings — PTC Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTCTPTC Therapeutics, Inc.

$6B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$167M+1.3% YoY

Gross Profit

$157M93.5% margin

Operating Income

-$200M-119.7% margin

Net Income

-$171M-102.1% margin

EPS (Diluted)

$-2.35

QoQ Revenue Growth

-22.9%

Cash Flow

Operating Cash Flow

-$166M

Free Cash Flow

-$193M

Stock-Based Comp.

$27M

Balance Sheet

Total Assets

$1.7B

Total Liabilities

$2.1B

Stockholders' Equity

-$347M

Cash & Equivalents

$280M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$167M	$165M	+1.3%
Gross Profit	$157M	$156M	+0.4%
Operating Income	-$200M	-$85M	-136.4%
Net Income	-$171M	-$143M	-19.3%

Geographic Segments

United States

$58M51%

Non-US

$56M49%